Hidden Heart Disease: New Scan Reveals Tiny Vessel Damage That Predicts Heart Attacks After Stents

For millions of patients who undergo a stent procedure to prop open clogged heart arteries, the operation is often declared a success. The major vessels are cleared, blood flows freely again on the angiography screen, and the patient goes home. Yet a troubling number of these people return within months or years with chest pain, heart attacks, or heart failure. A new two-center study from China suggests a reason why: the smallest blood vessels of the heart, invisible to standard angiography, may still be quietly failing — and a specialized nuclear scan can now detect that hidden damage and predict who will pay the price.

The study, published in the European Journal of Nuclear Medicine and Molecular Imaging, was led by Rong Wang of Gansu Provincial Hospital in Lanzhou and Wei Dong of Beijing Anzhen Hospital, Capital Medical University. The researchers enrolled 174 patients who had undergone percutaneous coronary intervention, or PCI, the umbrella term for stenting and related catheter-based procedures. Crucially, every participant had angiographically confirmed complete revascularization, meaning their large epicardial arteries showed no significant residual blockages. In other words, by conventional measures, these hearts had been fixed. The question was whether a deeper look would reveal lingering trouble.

The deeper look came from a technology called dynamic SPECT, abbreviated D-SPECT, which uses fast cadmium-zinc-telluride detectors to track a radioactive tracer moving through the heart muscle in real time. Traditional perfusion scans capture a single static snapshot of blood distribution, revealing only whether some regions of the heart look dimmer than others. Dynamic imaging goes further: by measuring how quickly the tracer arrives and washes out, clinicians can calculate absolute blood flow in milliliters per gram per minute, both at rest and during pharmacological stress, when a drug dilates the vessels to simulate exercise. The ratio of stress flow to rest flow yields the myocardial flow reserve, or MFR — a numerical gauge of how much extra blood delivery the heart can summon when demand rises.

A healthy heart can multiply its resting blood flow several-fold under stress. When that reserve falls below 2.0, it signals that the coronary microvasculature — the dense network of arterioles and capillaries too small to appear on any angiogram — cannot dilate properly. The researchers defined coronary microvascular disease, or CMD, as a global or territorial MFR below this threshold in the absence of any epicardial stenosis greater than 50 percent. This definition matters because microvascular dysfunction is increasingly recognized as a disease entity in its own right, one that causes ischemia, drives symptoms, and worsens outcomes even when the conduit arteries are wide open. Prior work has linked it to adverse remodeling of the heart muscle, diastolic dysfunction, and elevated risk in patients with diabetes and prior infarction.

The results were striking. Over a median follow-up of 12 months, during which some patients were followed for as long as 21 months, 42 of the 174 patients — 24.1 percent — suffered a major adverse cardiac event. The composite endpoint was deliberately broad, encompassing all-cause death, myocardial infarction, unscheduled coronary revascularization, stroke, hospitalization for heart failure, and rehospitalization for angina. When the investigators split the cohort by microvascular status, the difference was unmistakable: patients with CMD experienced significantly higher event rates, a separation visible on survival curves with a log-rank statistic of 11.375 and a p-value of 0.001.

What makes the finding clinically persuasive is that it survived rigorous statistical scrutiny. The team applied multivariable Cox regression, adjusting for traditional cardiovascular risk factors and for abnormal findings on conventional myocardial perfusion imaging. Even after accounting for these established predictors, CMD remained an independent predictor of adverse outcomes, carrying a hazard ratio of 2.46 — meaning patients with impaired flow reserve faced roughly two and a half times the risk of a major event compared with those whose microvessels functioned normally. The 95 percent confidence interval ranged from 1.27 to 4.76, and the p-value of 0.007 indicated the association was unlikely to be chance. Notably, the association held consistently across all prespecified patient subgroups.

The study also delivered a technical refinement with practical implications. Rather than relying solely on a single global MFR value averaged over the whole left ventricle, the researchers analyzed regional MFR — flow reserve measured separately in the territories supplied by each of the major coronary arteries. Statistical reclassification analyses quantified how much this regional approach added. The net reclassification improvement, or NRI, was 0.524, and the integrated discrimination improvement, or IDI, was 0.036, both statistically significant. In plain terms, looking at the heart territory by territory reclassified a meaningful fraction of patients into more accurate risk categories and improved the model’s ability to distinguish those who would have events from those who would not. A globally normal flow reserve can mask a severely diseased single territory, and the regional analysis catches what the average conceals.

The implications extend beyond the cardiology ward. Coronary microvascular dysfunction has long been difficult to assess outside specialized centers, historically requiring invasive catheter-based measurements such as the index of microcirculatory resistance, which involves threading a pressure-temperature sensor wire into the coronary artery. Noninvasive quantification with dynamic CZT-based SPECT offers a way to screen patients after PCI without additional catheterization. If confirmed, the approach could change post-procedural care: patients flagged with low flow reserve might be candidates for intensified medical therapy targeting the microcirculation — including aggressive risk-factor control, antiplatelet and lipid-lowering regimens, and emerging microvascular-directed treatments — while those with robust reserves might be spared unnecessary interventions and anxiety.

The authors are careful to frame their conclusions appropriately. This was a pilot study, exploratory in design, with a relatively modest sample size and a median follow-up of only one year — short by the standards of cardiovascular outcomes research. The researchers themselves call for validation in larger multi-center studies with longer follow-up and direct comparisons against invasive reference measurements. The cohort was drawn from two Chinese hospitals, Gansu Provincial Hospital and Beijing Anzhen Hospital, and whether the findings generalize to other populations remains to be demonstrated. Ethical approval was obtained from both institutions, and the work was funded by the National Natural Science Foundation of China along with provincial and municipal research programs.

Even with those caveats, the study adds an important piece to one of cardiology’s most persistent puzzles: why symptoms and events persist after anatomically successful revascularization. It reinforces a conceptual shift that has been gathering momentum in the field — that the coronary circulation must be evaluated as a whole, from the epicardial conduits down to the microscopic vessels where oxygen actually exchanges with heart muscle. For the roughly one in four patients in this cohort destined for a major cardiac event despite complete stenting, a 20-minute dynamic nuclear scan may soon offer something that angiography never could: a genuine look at the plumbing that matters most, and a head start on preventing the next crisis before it strikes.

Subject of Research: D-SPECT-derived myocardial flow reserve for detecting coronary microvascular disease and predicting outcomes after complete revascularization

Article Title: Prognostic value of D-SPECT-derived myocardial flow reserve in detecting coronary microvascular disease and predicting outcomes after complete revascularization: a two-center pilot study

Article References: Wang, R., Bai, J., Xie, P., Wang, H., Wang, X., Gao, Z., Chen, Y., Mi, H., & Dong, W. (2026). Prognostic value of D-SPECT-derived myocardial flow reserve in detecting coronary microvascular disease and predicting outcomes after complete revascularization: a two-center pilot study. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08162-0

Image Credits: AI Generated

DOI: 10.1007/s00259-026-08162-0

Keywords: D-SPECT, myocardial flow reserve, coronary microvascular disease, percutaneous coronary intervention, major adverse cardiac events, nuclear cardiology, SPECT imaging, coronary microcirculation, prognosis, revascularization, cardiac imaging, Prognostic